Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2005

01-06-2005 | Review Article

First-Episode Schizophrenia

A Focus on Pharmacological Treatment and Safety Considerations

Authors: Dr Deanna L. Kelly, Robert R. Conley, William T. Carpenter

Published in: Drugs | Issue 8/2005

Login to get access

Abstract

Schizophrenia is a debilitating disorder, which is usually chronic, and is one of the most devastating medical illnesses. Early and appropriate treatment with antipsychotics is an important strategy for patients with first-episode schizophrenia. However, there are many possible safety issues for patients with schizophrenia that should be considered and properly addressed.
Depressive symptoms and suicidal behaviour commonly occur in first-episode schizophrenic patients, and every effort should be made to treat and minimise these symptoms. There are also important issues and considerations in young and first-episode patients that should also be considered in the emergency treatment setting and for minimising medication nonadherence in this population. Most importantly, adverse effects should be considered, minimised and addressed. While first- and second-generation antipsychotics (SGAs) both appear to offer similar efficacy for amelioration of positive symptoms in first-episode patients, SGAs may offer better tolerability, specifically regarding extrapyramidal symptoms (EPS) and tardive dyskinesia risk, and some prolactin-sparing benefits. However, these medications do cause a host of adverse effects, including weight gain, metabolic disturbances, corrected QT interval prolongation and prolactin-related adverse effects, which are important considerations relating to both the short- and long-term safety of patients with schizophrenia being treated with SGAs. Clozapine and olanzapine are most likely to cause weight gain and metabolic effects, while risperidone is more likely to cause EPS and prolactin elevations. Most antipsychotics should be used in low doses to minimise adverse effects and each medication should be optimised in a highly individualised way to maximise adherence and treatment outcomes and minimise tolerability and safety concerns. At some point in their lives, these patients will most probably experience periods of depression, suicidal behaviours, adverse effects and nonadherence, and every effort should be made to minimise or prevent these from occurring. Thus, safety concerns in this group of young patients, in the beginning of their first psychotic episode, are a major issue as they are starting a journey of antipsychotic treatment that is likely to last for the remainder of their lives.
Literature
1.
2.
Caldwell CB, Gottesman JI. Schizophrenia: a high risk factor for suicide. Clues to risk reduction. Suicide Life Threat Behav 1992; 22: 479–93
3.
Dequardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998; 59 Suppl. 19: 9–17
4.
Lieberman JA, Alvir J, Woerner M, et al. Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital. Schizophr Bull 1992; 18: 351–71PubMedCrossRef
5.
Mojtabai R, Bromet EJ, Harvey PD, et al. Neuropsychological differences between first-admission schizophrenia and psychotic affective disorders. Am J Psychiatry 2000; 157: 1453–60PubMedCrossRef
6.
Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001; 158: 1835–42PubMedCrossRef
7.
Hafner H, Loffler W, Maurer K, et al. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 1999; 100: 105–18PubMedCrossRef
8.
Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286–90PubMedCrossRef
9.
Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39: 69–72PubMedCrossRef
10.
Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241–7PubMedCrossRef
11.
Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implication for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 9: 5–9
12.
Falloon IR, Kydd RR, Coverdale JH, et al. Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull 1996; 22(2): 271–82PubMedCrossRef
13.
McGlashan TH, Miller TJ, Woods SW. Pre-onset detection and intervention research in schizophrenia psychoses: current estimates of benefit and risk. Schizophr Bull 2001; 27: 563–70PubMedCrossRef
14.
Ucok A, Polat A, Gene A, et al. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 2004; 38: 163–8PubMedCrossRef
15.
Carpenter Jr WT, Appelbaum PS, Levine RJ. The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. Am J Psychiatry 2003; 160: 356–62PubMedCrossRef
16.
Carpenter WT, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 1997; 54: 401–7PubMedCrossRef
17.
18.
Wyatt RJ, Henter ID, Barkto JJ. The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry 1999; 46: 1092–105PubMedCrossRef
19.
Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull 1997; 23(1): 3–9PubMedCrossRef
20.
Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendation. Schizophr Bull 1998; 24: 1–10PubMedCrossRef
21.
The Expert Consensus Guideline Series: treatment of schizophrenia. J Clin Psychiatry 1999; 60 Suppl. 11: 8–80
22.
Johnstone EC, MacMillan JF, Crow TJ. The occurrence of organic disease of possible or probable aetiological significance in a population of 268 cases of first episode schizophrenia. Psychol Med 1987; 17: 371–9PubMedCrossRef
23.
Sheitman BB, Lee H, Strauss R, et al. The evaluation and treatment of first-episode psychosis. Schizophr Bull 1997; 23(4): 653–61PubMedCrossRef
24.
Pikalov A. American Psychiatric Association practice guidelines for the treatment of psychiatric disorders: compendium 2002. In: APA Steering Committee on Practice Guidelines, editors. Washington, DC: American Psychiatric Publishing, 2002
25.
Bromet EJ, Schwartz JE, Fenning S, et al. The epidemiology of psychosis: the Suffolk County mental health project. Schizophr Bull 1992; 18(2): 243–55PubMedCrossRef
26.
American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
27.
Frances A, First MB, Pincus HA. DSM-IV guidebook. Washington, DC: American Psychiatric Press, 1995
28.
Fenton WS. Course and outcome in schizophrenia. Curr Opin Psychiatry 1997; 10(1): 40–4CrossRef
29.
Keshavan MS, Schooler NR. First-episode studies in schizophrenia: criteria and characterization. Schizophr Bull 1992; 18: 591–613CrossRef
30.
Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 Suppl. 12: 5–19
31.
Tauscher J, Kapur S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 2001; 15: 671–8PubMedCrossRef
32.
Oosthuizen P, Emsley RA, Turner J, et al. Determining the optimal dose of haloperidol in first-episode psychosis. J Psychopharmacol 2001; 15: 251–5PubMedCrossRef
33.
Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotics drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396–404PubMedCrossRef
34.
Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995–1003PubMed
35.
Schotte A, Janssen PFM, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57–73PubMedCrossRef
36.
Emsley RA, The Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind muticenter study. Schizophr Bull 1999; 25: 721–9PubMedCrossRef
37.
Zalsman G, Carmon E, Martin A, et al. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 2003; 13: 319–27PubMedCrossRef
38.
Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997; 17: 308–13PubMedCrossRef
39.
Malla AK, Norman RMG, Scholten DJ, et al. A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic. J Clin Psychiatry 2001; 62: 179–84PubMedCrossRef
40.
Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87–96PubMedCrossRef
41.
Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999; 156: 79–87PubMed
42.
Bobes J, Gilbert J, Ciudad A, et al. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 473–81PubMedCrossRef
43.
Tauscher-Wisniewski S, Kapur S, Tauscher J, et al. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002; 11: 992–7CrossRef
44.
McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61(4): 252–60PubMedCrossRef
45.
Good KP, Kiss I, Buiteman C, et al. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry Suppl 2002; 43: s45–9PubMedCrossRef
46.
Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–13PubMed
47.
Benkert O, Muller-Siecheneder F, Wetzel H. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol 1995; 5: 43–53PubMedCrossRef
48.
Taylor DM. Aripiprazole: a review of its pharmacology and clinical use. Int J Clin Pract 2003; 57: 49–54PubMed
49.
Fleischhacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994; 89 Suppl. 382: 11–5
50.
Barton M, Furrer J. Cardiovascular consequences of the obesity pandemic: need for action. Expert Opin Investig Drugs 2003; 12: 1757–9PubMedCrossRef
51.
Janno S, Holi M, Tuisku K, et al. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004; 161: 160–3PubMedCrossRef
52.
Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001; 62: 15–8PubMed
53.
Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16–21PubMedCrossRef
54.
Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. 2nd ed. Caddo (OK): Professional Communications Inc., 2003
55.
Seretti A, De Ronchi D, Lorenzi C, et al. New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 2004; 11: 343–58CrossRef
56.
Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999; 60 Suppl. 23: 5–9
57.
Aguilar EJ, Matcheri SK, Martinez-Quiles MD, et al. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry 1994; 151: 1819–21PubMed
58.
Kane JM, Woerner M, Borenstein M, et al. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254–8PubMed
59.
Chakos MH, Alvir JMJ, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; 53: 313–9PubMedCrossRef
60.
Oosthuizen PP, Emsley RA, Maritz JS, et al. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64: 1075–80PubMedCrossRef
61.
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–25PubMedCrossRef
62.
Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63 Suppl. 4: 12–9
63.
Beasley CM, Dellva MA, Tamura RN, et al. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30PubMedCrossRef
64.
Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 2000; 15: 506–14PubMedCrossRef
65.
Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716–9PubMed
66.
Flegal KM, Carroll MD, Kuczmarski RJ, et al. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 1998 Jan; 22(1): 39–47PubMedCrossRef
67.
Caballero E. Obesity, diabetes, and the metabolic syndrome: new challenges in antipsychotic drug therapy. CNS Spectr 2003; 8: 19–22PubMed
68.
Ryan MC, Flanagan S, Kinsella U, et al. The effects of atypical antipsychotics on visceral fat distribution in first-episode, drug-naive patients with schizophrenia. Life Sci 2004; 74: 1999–2008PubMedCrossRef
69.
Aronne LJ. Epidemiology, morbidity and treatment of overweight and obesity. J Clin Psychiatry 2001; 62 Suppl. 23: 13–22
70.
Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 Suppl. 7: 22–31
71.
Physician’s desk reference. 56th ed. Montvale (NJ): Medical Economics Company Inc., 2003
72.
Tandon R, Harrigan E, Zorn S. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159–77
73.
Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997; 58 Suppl. 10: 45–9
74.
Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92–100PubMedCrossRef
75.
Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255–62PubMedCrossRef
76.
Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia: the Risperidone USA-79 Study Group. N Engl J Med 2002; 346: 16–22PubMedCrossRef
77.
Brecher M, Rak IW, Westhead EK, et al. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287–92CrossRef
78.
Emsley R, Turner HJ, Schronen J, et al. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol. Epub 2005 Mar 1: 1–8
79.
Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002; 63(6): 516–23PubMedCrossRef
80.
Arato M, O’Connor R, Meltzer HY, et al. A 1-year, double-blind, placebo controlled trial of ziprasidone 40, 80, and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17: 207–15PubMedCrossRef
81.
Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003 Dec; 6(4): 325–37
82.
Poyurovsky M, Paskinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first episode schizophrenia: a double-blind placebo-controlled study of fluoxetine addition. Am J Psychiatry 2002; 159: 1058–60PubMedCrossRef
83.
Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002; 41: 337–43PubMedCrossRef
84.
Martin A, L’Ecuyer S. Triglycerides, cholesterol and weight changes among risperidone-treated youths: a retrospective study. Eur Child Adolesc Psychiatry 2002; 11: 129–33PubMedCrossRef
85.
Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics. J Child Adolesc Psychopharmacol 1998; 8: 151–9PubMedCrossRef
86.
Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001; 11: 415–24PubMedCrossRef
87.
Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284–9PubMedCrossRef
88.
Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 Suppl. 27: 15–26
89.
Koro CE, Fedder DO, Weiss SS, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325: 325–31CrossRef
90.
Koller E, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002 Jul; 22(7): 841–52PubMedCrossRef
91.
Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with second-generation antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002; 14(1): 59–64PubMed
92.
Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64(7): 701–23PubMedCrossRef
93.
Fertig MK, Brooks VC, Shelton PS, et al. Hyperglycemia associated with olanzapine. J Clin Psychiatry 1998; 59: 687–9PubMedCrossRef
94.
Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine [letter]. Am J Psychiatry 1999; 156: 970PubMed
95.
Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999; 156: 1471PubMed
96.
Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical antipsychotic drugs: a report of three cases. Diabet Med 2000; 17: 484–6PubMedCrossRef
97.
Bettinger TL, Mendelson SC, Dorson PG, et al. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34: 865–7PubMedCrossRef
98.
Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 31: 742–9CrossRef
99.
Biswas PN, Wilton LV, Pearce GL, et al. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 2001; 15: 265–71CrossRef
100.
Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001; 50: 148–9PubMedCrossRef
101.
Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001; 286: 2547–8PubMedCrossRef
102.
Sheitman BB, Bird PM, Binz W, et al. Olanzapine-induced elevation of plasma triglycerides levels. Am J Psychiatry 1999; 156: 1471–2PubMed
103.
Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglycerides levels. J Clin Psychiatry 1999; 60: 767–70PubMedCrossRef
104.
Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369–74PubMedCrossRef
105.
Koro CE, Fedder DO, Weiss S, et al. An assessment of the independent effect of olanzapine and risperidone exposure on the risk of the hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021–6PubMedCrossRef
106.
Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63(5): 425–33PubMedCrossRef
107.
Lebovitz HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 2003; 74: 277–90PubMedCrossRef
108.
Yassa R, Lal S. Impaired sexual intercourse as a complication of tardive dyskinesia. Am J Psychiatry 1985; 142: 1514–5PubMed
109.
Meston CM, Gorzalka BB. Psychoactive drugs and human sexual behaviour: the role of serotonergic activity. J Psychoactive Drugs 1992; 24: 1–40PubMedCrossRef
110.
Pollack MH, Rosenbaum JF. Management of antidepressant-induced side effects: a practical guide for the clinician. J Clin Psychiatry 1987; 48: 3–8PubMed
111.
Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med 1992; 22: 305–27PubMed
112.
Tamminga CA, Mack RJ, Granneman GR, et al. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997; 12 Suppl. 1: S29–35PubMedCrossRef
113.
Shader RI, DiMascio A. Endocrine effects of psychotropic drugs. VI: male sexual function. Conn Med 1968; 32: 847–8
114.
Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic patients. J Nerv Ment Dis 1982; 170(8): 463–7PubMedCrossRef
115.
Sullivan G, Lukoff D. Sexual side effects of antipsychotic mediation: evaluation and interventions. Hosp Community Psychiatry 1990; 41: 1238–41PubMed
116.
Macdonald S, Halliday J, MacEwan T, et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunctions. Case control study. Br J Psychiatry 2003; 182: 50–6
117.
Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28 Suppl. 1: 53–67CrossRef
118.
Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 Suppl. 4: 56–62
119.
Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28 Suppl. 2: 97–108CrossRef
120.
Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19: 57–61PubMedCrossRef
121.
Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159: 133–5PubMedCrossRef
122.
Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158(5): 765–74PubMedCrossRef
123.
Mullen B, Brar JS, Vagnucci AH, et al. Frequency of sexual dysfunction in patients with schizophrenia on haloperidol, clozapine, or risperidone. Schizophr Res 2001; 48: 155–8PubMedCrossRef
124.
Bobes J, Garc A-Portilla MP, Rejas J, et al. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE group. J Sex Marital Ther 2003; 29: 125–47PubMedCrossRef
125.
Shiwach RS, Carmody TJ. Prolactogenic effects of risperidone in male patients: a preliminary study. Acta Psychiatr Scand 1998; 98: 81–3PubMedCrossRef
126.
Mabini R, Wegowske G, Baker FM. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone. Psychiatr Serv 2000; 51: 983–5PubMedCrossRef
127.
128.
Nicholson R, McCurley R. Risperidone-associated priapism. J Clin Psychopharmacol 1997; 7(2): 133–4CrossRef
129.
Ernes CE, Millson RC. Risperidone-induced priapism. Can J Psychiatry 1994; 39(5): 315–6
130.
Raja M. Risperidone-induced absence of ejaculation. Int Clin Psychopharmacol 1999; 4(5): 317–9
131.
Dickson RA, Dalby JT, Williams R, et al. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995; 152: 1102–3PubMed
132.
Kim Y-K, Kim L, Lee M-S. Risperidone and associated amenorrhea: a report of 5 cases. J Clin Psychiatry 1999; 60: 315–7PubMedCrossRef
133.
Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18PubMedCrossRef
134.
Crawford AMK, Beasley Jr CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26: 41–54PubMedCrossRef
135.
Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsiveness of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001; 251: 141–6PubMedCrossRef
136.
Compton MT, Miller AH. Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiatry 2001; 62(5): 362–6PubMedCrossRef
137.
Arvanitis L, Miller B. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42(4): 233–46
138.
Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54(6): 549–57PubMedCrossRef
139.
King DJ, Link CGG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998; 37: 139–46CrossRef
140.
Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16(2): 158–69PubMedCrossRef
141.
Goldstein JM, Cantillon M. Low incidence of reproductive/ hormonal side effects with Seroquel (quetiapine) is supported by its lack of elevation of plasma prolactin concentrations [poster]. Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec 7–12; Hawaii
142.
Pais VM, Ayvazian PJ. Priapism from quetiapine overdose: first report and proposal of mechanism. Urology 2001; 58(3): 462PubMedCrossRef
143.
Oenanthe J, Burgoyne K, Smith M, et al. Prolactin levels and new antipsychotics [poster no. 10064]. European College of Neuropsychopharmacology; 1998 Jul 12–16; Glasgow
144.
Reeves RR, Kimble R. Prolonged erections associated with ziprasidone treatment: a case report. J Clin Psychiatry 2003; 64: 97–8PubMedCrossRef
145.
Reeves RR, Mack JE. Priapism associated with two atypical antipsychotic agents. Pharmacotherapy 2002; 22: 1070–3PubMedCrossRef
146.
Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 732–71CrossRef
147.
Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Aripiprazole Study Group. J Clin Psychiatry 2003; 64: 1048–56CrossRef
148.
Wudarsky M, Nicolson R, Hamberger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999; 9: 239–45PubMedCrossRef
149.
Gupta S, Frank B, Madhusoodanan S. Risperidone-associated galactorrhea in a male teenager. J Am Acad Child Adolesc Psychiatry 2001; 40: 504–5PubMedCrossRef
150.
Masi G, Cosenza A, Mucci M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol 2001; 11: 389–94PubMedCrossRef
151.
Matsuyama J, Eshima N, Fukunaga T, et al. Various risks of osteoporosis in patients with pituitary adenomas. J Bone Miner Metab 2003; 21: 91–7PubMedCrossRef
152.
Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003; 64: 761–6PubMedCrossRef
153.
Clevenger CV, Plank TL. Prolactin as an autocrine/paracrine factor in breast tissue. J Mammary Gland Biol Neoplasia 1997; 2: 59–68PubMedCrossRef
154.
Wang PS, Walker AM, Tsuang MT, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147–54PubMedCrossRef
155.
Clevenger CV, Furth PA, Hankinson SE, et al. The role of prolactin in mammary carcinoma. Endocr Rev 2003; 24: 1–27PubMedCrossRef
156.
Lalonde FM, Myslobodsky M. Are dopamine antagonists a risk factor for breast cancer? An answer from Parkinson’s disease. Breast 2003; 12: 280–2PubMedCrossRef
157.
Faber TS, Zehender M, Just H. Drug-induced torsades de pointes: incidence, management and prevention. Drug Saf 1994; 11(6): 463–76PubMedCrossRef
158.
159.
Reilly JG, Ayis SA, Ferner IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048–52PubMedCrossRef
160.
Food and Drug Administration Center for Drug Evaluation Research. Transcript of Psychopharmacological Drugs Advisory Committee July 19,2000. Ziprasidone briefing document [online]. Available from URL: http://​www.​fda.​gov/​ohrms/​ dockets/ac/00/backgrd/3619b1a.pdf [Accessed 2004 Mar 30]
161.
Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997; 31: 867–70PubMed
162.
Dineen S, Withrow K, Voronovitch L, et al. QTc prolongation and high-dose olanzapine. Pyschosomatics 2003; 44: 174–5CrossRef
163.
164.
Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001; 20: 215–9PubMedCrossRef
165.
Furst BA, Champion KM, Pierre JM, et al. Possible association of QTc interval prolongation with coadministration of quetiapine and lovastatin. Biol Psychiatry 2002; 51: 264–5PubMedCrossRef
166.
Thomas SHL. Drugs, QT abnormalities, and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994; 13: 77–102PubMed
167.
Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Eur Heart J 2000; 21: 1216–31PubMedCrossRef
168.
Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000; 25(2): 154–60PubMed
169.
Marfella R, Napo F, De Angelis L, et al. The effect of acute hyperglycemia on QTc duration in healthy man. Diabetologia 2000; 43: 571–5PubMedCrossRef
170.
Conley RR. Risperidone side effects. J Clin Psychiatry 2000; 61 Suppl. 8: 20–3
171.
Merlo MCG, Hofer H, Gekle W, et al. Risperidone, 2 mg/day vs 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry 2002; 63: 885–91PubMedCrossRef
172.
Conley RR, Meltzer HY. Adverse events related to olanzapine. J Clin Psychiatry 2000; 61 Suppl. 8: 26–9
173.
Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 2002; 41: 439–46CrossRef
174.
Fraunfelder FW. Twice-yearly exams unnecessary for patients taking quetiapine. Am J Ophthalmol 2004 Nov; 138(5): 870–1PubMedCrossRef
175.
Kane JM. Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry 2003; 64 Suppl. 19: 19–25
176.
DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004 May; 26(5): 649–66PubMedCrossRef
177.
Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsychotic drugs. Drug Saf. 1993 Dec; 9(6): 429–36PubMedCrossRef
178.
Hafner H, Maurer K, Loffler W, et al. Onset and early course of schizophrenia. In: Hafner H, Gattaz WF, editors. Search for the causes of schizophrenia. Vol. III. Berlin: Springer, 1995: 43–66CrossRef
179.
McGlashan TH, Carpenter WT. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 33: 231–9PubMedCrossRef
180.
181.
Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSMIV. Schizophr Bull 1991; 17: 75–98PubMedCrossRef
182.
Moller H-J, von Zerssen D. Depression in schizophrenia. In: Burrows GD, Norman TR, Rubinstein G, editors. Handbook of studies on schizophrenia: part I. Amsterdam: Elsevier, 1986: 183–91
183.
Subotnick KL, Nuechterlein KH, Asarnow RF, et al. Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. Am J Psychiatry 1997; 154: 1551–6
184.
Smith GN, Lang DJ, Kopala LC, et al. Developmental abnormalities of the hippocampus in first-episode schizophrenia. Biol Psychiatry 2003; 53: 555–61PubMedCrossRef
185.
Siris SG. Depression in schizophrenia. In: Shriqui CL, Nasrallah HA, editors. Contemporary issues in the treatment of schizophrenia. Washington, DC: American Psychiatric Press, 1995: 155–66
186.
Barnes TRE, Curson DA, Liddle PF, et al. The nature and prevalence of depression in chronic schizophrenic inpatients. Br J Psychiatry 1989; 154: 486–91PubMedCrossRef
187.
Drake RE, Gates C, Whitaker A, et al. Suicide among schizophrenics: a review. Compr Psychiatry 1985; 26: 90–100PubMedCrossRef
188.
Roy A, Thompson R, Jennedy S. Depression in chronic schizophrenia. Br J Psychiatry 1983; 142: 465–70PubMedCrossRef
189.
Caldwell CB, Gottesman JI. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 1990; 16: 571–89PubMedCrossRef
190.
Hafner H, Bickel H. Physical morbidity and mortality in psychiatric patients. In: Ohman R, Freeman H, Holmkvist A, et al., editors. Interaction between mental and physical illness. Berlin: Springer, 1988: 29–47
191.
192.
Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993; 163: 183–9PubMedCrossRef
193.
Addington J, Ledger E, Addington D. Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry 2003; 48: 204–7PubMed
194.
Rossau CD, Mortensen PB. Risk factors for suicide in patients with schizophrenia: nested case-control study. Br J Psychiatry 1997; 171: 355–9PubMedCrossRef
195.
Cohen S, Lavelle J, Rich CL, et al. Rates and correlates of suicide attempts in first-admission psychotic patients. Acta Psychiatr Scand 1994; 90: 167–71PubMedCrossRef
196.
Kreyenbuhl J, Kelly DL, Conley RR. Circumstances of suicide among patients with schizophrenia. Schizophr Res 2002; 58(2–3): 253–61PubMedCrossRef
197.
Koreen AR, Siris SG, Chakos M, et al. Depression in first-episode schizophrenia. Am J Psychiatry 1993; 150: 1643–8PubMed
198.
Addington D, Addington J, Patten S. Depression in people with first-episode schizophrenia. Br J Psychiatry Suppl 1998; 172: 90–2PubMedCrossRef
199.
Alvarez E, Bobes J, Gomez JC, et al. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia: a naturalistic study. Europa Study Group. Eur Neuropsychopharmacol 2003; 13: 39–48
200.
Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001; 62: 757–71PubMedCrossRef
201.
Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSept). International Suicide Prevention Trial Study Group. Arch Gen Psychiatry 2003; 60: 82–91
202.
Kolivakis TT, Margolese HC, Beauclair L, et al. Clozapine for first-episode schizophrenia [letter]. Am J Psychiatry 2002; 159: 317PubMedCrossRef
203.
Rowlands RP. Auditing first episode psychosis: giving meaning to clinical governance. Int J Clin Pract 2001; 55: 669–72PubMed
204.
Neborsky R, Janowsky D, Munson E, et al. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol: behavioral considerations. Arch Gen Psychiatry 1981; 38(2): 195–9PubMedCrossRef
205.
Coffman JA, Nasrallah HA, Lyskowski J, et al. Clinical effectiveness of oral and parenteral rapid neuroleptization. J Clin Psychiatry 1987; 48(1): 20–4PubMed
206.
Tupin JP. Focal neuroleptization: an approach to optimal dosing for initial and continuing therapy. J Clin Psychopharmacol 1985; 5 (3 Suppl.): 15S–21SPubMed
207.
Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15(4): 335–40PubMedCrossRef
208.
Foster S, Kessel J, Berman ME, et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997; 12(3): 175–9PubMedCrossRef
209.
Sheline Y, Nelson T. Patient choice: deciding between psychotropic medication and physical restraints in an emergency. Bull Am Acad Psychiatry Law 1993; 212: 321–9
210.
Citrome L, Volavka J. Violent patients in the emergency setting. Psychiatr Clin North Am 1999; 22: 789–801PubMedCrossRef
211.
Kamin J, Manwani S, Hughes D. Emergency psychiatry: extrapyramidal side effects in the psychiatric emergency service. Psychiatr Serv 2000; 51: 287–9PubMedCrossRef
212.
Sharif ZA. Common treatment goals of antipsychotics: acute treatment. J Clin Psychiatry 1998; 59 Suppl. 19: 5–8
213.
Lader M. Neuroleptic-induced deficit syndrome: old problem, new challenge. J Psychopharmacol 1993; 7(4): 392–3PubMedCrossRef
214.
Currier G, Simpson G. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62(3): 153–7PubMedCrossRef
215.
Raja M, Azzoni A. Second-generation antipsychotics in the emergency care setting: a prospective naturalistic study. Gen Hosp Psychiatry 2000; 22(2): 107–14PubMedCrossRef
216.
Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis: Ziprasidone IM Study Group. J Clin Psychiatry 2000; 61: 933–41PubMedCrossRef
217.
Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149–51PubMedCrossRef
218.
Feifel D. Rationale and guidelines for the inpatient treatment of acute psychosis. J Clin Psychiatry 2000; 61 Suppl. 14: 27–32
219.
Currier G, Allen M. American Association for Emergency Psychiatry Survey [poster]. The American Psychiatric Association 51st Institute on Psychiatric Services; 1999 Oct 29–Nov 2; New Orleans
220.
221.
Doering S, Muller E, Kopcke W, et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998; 24: 87–98PubMedCrossRef
222.
Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the ‘revolving door’ phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995; 152: 856–61PubMed
223.
Kent S, Yellowlees P. Psychiatric and social reasons for frequent hospitalization. Hosp Community Psychiatry 1994; 45: 347–50PubMed
224.
Sullivan G, Wells KB, Morgenstern H, et al. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 1995; 152: 1749–56PubMed
225.
Dunbar-Jacob J, Erlen JA, Schlenk EA, et al. Adherence in chronic disease. Annu Rev Nurs Res 2000; 18: 48–90PubMed
226.
Kyngas HA, Kroll T, Duffy ME. Compliance in adolescents with chronic diseases: a review. J Adolesc Health 2000; 26: 379–88PubMedCrossRef
227.
Viller F, Guillemin F, Briancon S, et al. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 1999; 26: 2114–22PubMed
228.
Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003; 25: 2289–304PubMedCrossRef
229.
Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57: 53–60PubMed
230.
Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63(12): 1121–8PubMedCrossRef
231.
Voruganti L, Cortese L, Owyeumi L, et al. Switching form conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57: 201–8PubMedCrossRef
232.
Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002; 40: 630–9PubMedCrossRef
233.
Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103–8PubMedCrossRef
234.
Garavan J, Browne M, Gervin M, et al. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics. Compr Psychiatry 1998; 39: 215–9PubMedCrossRef
235.
Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programs? A systematic review. Psychol Med 2003; 33: 1149–60PubMedCrossRef
236.
Robinson DG, Woerner MG, Alvir JMJ, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 2002; 57: 209–19PubMedCrossRef
237.
Helgason L. Twenty years’ follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand 1990; 81: 231–5PubMedCrossRef
238.
Szymanski SR, Cannon TD, Gallacher F, et al. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996; 153: 519–25PubMed
239.
Garcia Cabeza I, Sanchez Diaz El, Sanz Amador M, et al. Factors related to treatment adherence in schizophrenic patients. Actas Esp Psiquiatr 1999; 27: 211–6PubMed
240.
Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23(4): 637–51PubMedCrossRef
241.
Dencker SJ, Lieberman RP. From compliance to collaboration in the treatment of schizophrenia. Int Clin Psychopharmacol 1995; 9 Suppl. 5: 75–8CrossRef
Metadata
Title
First-Episode Schizophrenia
A Focus on Pharmacological Treatment and Safety Considerations
Authors
Dr Deanna L. Kelly
Robert R. Conley
William T. Carpenter
Publication date
01-06-2005
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565080-00006

Other articles of this Issue 8/2005

Drugs 8/2005 Go to the issue

Adis Drug Evaluation

Enfuvirtide: A Review of its Use in the Management of HIV Infection

Therapy in Practice

The Role of Topical Retinoids in the Treatment of Photoaging

Review Article

Angiotensin Antagonism in Coronary Artery Disease

Current Opinion

Enteric-Coated Mycophenolate Sodium

Leading Article

Omega-3 Fatty Acids in the Treatment of Psychiatric Disorders

Review Article

Bacterial Meningitis in Children